Insulet PE Ratio 2012-2025 | PODD
Current and historical p/e ratio for Insulet (PODD) from 2012 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Insulet PE ratio as of February 10, 2026 is 56.03.
| Insulet PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-02-10 | 252.41 | 73.16 | |
| 2025-09-30 | 308.73 | $3.45 | 89.49 |
| 2025-06-30 | 314.18 | $3.29 | 95.50 |
| 2025-03-31 | 262.61 | $5.56 | 47.23 |
| 2024-12-31 | 261.07 | $5.79 | 45.09 |
| 2024-09-30 | 232.75 | $5.84 | 39.85 |
| 2024-06-30 | 201.80 | $5.50 | 36.69 |
| 2024-03-31 | 171.40 | $3.30 | 51.94 |
| 2023-12-31 | 216.98 | $2.91 | 74.56 |
| 2023-09-30 | 159.49 | $1.71 | 93.27 |
| 2023-06-30 | 288.34 | $0.89 | 323.98 |
| 2023-03-31 | 318.96 | $0.00 | 0.00 |
| 2022-12-31 | 294.39 | $0.06 | 4906.50 |
| 2022-09-30 | 229.40 | $0.24 | 955.83 |
| 2022-06-30 | 217.94 | $0.50 | 435.88 |
| 2022-03-31 | 266.39 | $0.63 | 422.84 |
| 2021-12-31 | 266.07 | $0.23 | 1156.83 |
| 2021-09-30 | 284.23 | $-0.45 | 0.00 |
| 2021-06-30 | 274.51 | $-0.46 | 0.00 |
| 2021-03-31 | 260.92 | $0.13 | 2007.08 |
| 2020-12-31 | 255.63 | $0.10 | 2556.30 |
| 2020-09-30 | 236.59 | $0.44 | 537.70 |
| 2020-06-30 | 194.26 | $0.28 | 693.79 |
| 2020-03-31 | 165.68 | $0.08 | 2071.00 |
| 2019-12-31 | 171.20 | $0.18 | 951.11 |
| 2019-09-30 | 164.93 | $0.26 | 634.35 |
| 2019-06-30 | 119.38 | $0.28 | 426.36 |
| 2019-03-31 | 95.09 | $0.23 | 413.43 |
| 2018-12-31 | 79.32 | $0.05 | 1586.40 |
| 2018-09-30 | 105.95 | $-0.23 | 0.00 |
| 2018-06-30 | 85.70 | $-0.30 | 0.00 |
| 2018-03-31 | 86.68 | $-0.40 | 0.00 |
| 2017-12-31 | 69.00 | $-0.46 | 0.00 |
| 2017-09-30 | 55.08 | $-0.50 | 0.00 |
| 2017-06-30 | 51.31 | $-0.51 | 0.00 |
| 2017-03-31 | 43.09 | $-0.46 | 0.00 |
| 2016-12-31 | 37.68 | $-0.51 | 0.00 |
| 2016-09-30 | 40.94 | $-0.83 | 0.00 |
| 2016-06-30 | 30.24 | $-1.11 | 0.00 |
| 2016-03-31 | 33.16 | $-1.30 | 0.00 |
| 2015-12-31 | 37.81 | $-1.29 | 0.00 |
| 2015-09-30 | 25.91 | $-0.91 | 0.00 |
| 2015-06-30 | 30.99 | $-0.77 | 0.00 |
| 2015-03-31 | 33.35 | $-1.03 | 0.00 |
| 2014-12-31 | 46.06 | $-0.93 | 0.00 |
| 2014-09-30 | 36.85 | $-0.87 | 0.00 |
| 2014-06-30 | 39.67 | $-1.07 | 0.00 |
| 2014-03-31 | 47.42 | $-0.74 | 0.00 |
| 2013-12-31 | 37.10 | $-0.83 | 0.00 |
| 2013-09-30 | 36.24 | $-1.00 | 0.00 |
| 2013-06-30 | 31.41 | $-0.87 | 0.00 |
| 2013-03-31 | 25.86 | $-0.97 | 0.00 |
| 2012-12-31 | 21.22 | $-1.08 | 0.00 |
| 2012-09-30 | 21.58 | $-1.17 | 0.00 |
| 2012-06-30 | 21.37 | $-1.20 | 0.00 |
| 2012-03-31 | 19.14 | $-1.32 | 0.00 |
| 2011-12-31 | 18.83 | $-1.23 | 0.00 |
| 2011-09-30 | 15.26 | $-1.43 | 0.00 |
| 2011-06-30 | 22.17 | $-1.44 | 0.00 |
| 2011-03-31 | 20.62 | $-1.38 | 0.00 |
| 2010-12-31 | 15.50 | $-1.53 | 0.00 |
| 2010-09-30 | 14.14 | $-1.45 | 0.00 |
| 2010-06-30 | 15.05 | $-2.03 | 0.00 |
| 2010-03-31 | 15.09 | $-2.40 | 0.00 |
| 2009-12-31 | 14.28 | $-2.74 | 0.00 |
| 2009-09-30 | 11.23 | $-3.34 | 0.00 |
| 2009-06-30 | 7.70 | $-3.21 | 0.00 |
| 2009-03-31 | 4.10 | $-3.35 | 0.00 |
| 2008-12-31 | 7.72 | $-3.37 | 0.00 |
| 2008-09-30 | 13.92 | $-2.94 | 0.00 |
| 2008-06-30 | 15.73 | $-2.71 | 0.00 |
| 2008-03-31 | 14.40 | $-2.83 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $18.052B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $190.250B | 21.25 |
| EssilorLuxottica (ESLOY) | France | $141.053B | 0.00 |
| Stryker (SYK) | United States | $140.785B | 27.01 |
| Boston Scientific (BSX) | United States | $136.192B | 31.14 |
| Medtronic (MDT) | Ireland | $131.676B | 18.24 |
| Medline (MDLN) | United States | $59.144B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.791B | 0.00 |
| Agilent Technologies (A) | United States | $38.383B | 24.26 |
| ResMed (RMD) | United States | $37.110B | 24.78 |
| GE HealthCare Technologies (GEHC) | United States | $36.492B | 17.45 |
| Koninklijke Philips (PHG) | Netherlands | $27.828B | 18.18 |
| Terumo (TRUMY) | Japan | $19.515B | 22.05 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.087B | 10.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.556B | 0.00 |
| Baxter (BAX) | United States | $10.214B | 8.24 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.023B | 28.85 |
| Demant (WILYY) | Denmark | $7.483B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.410B | 13.43 |
| Envista Holdings (NVST) | United States | $3.825B | 21.94 |
| BillionToOne (BLLN) | United States | $3.824B | 0.00 |
| ICU Medical (ICUI) | United States | $3.739B | 23.74 |
| Prestige Consumer Healthcare (PBH) | United States | $3.147B | 14.35 |
| Haemonetics (HAE) | United States | $3.079B | 13.70 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.007B | 0.00 |
| Neogen (NEOG) | United States | $2.230B | 48.81 |
| Perrigo (PRGO) | Ireland | $1.971B | 4.94 |
| LeMaitre Vascular (LMAT) | United States | $1.960B | 39.45 |
| QuidelOrtho (QDEL) | United States | $1.878B | 12.07 |
| AtriCure (ATRC) | United States | $1.831B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.699B | 16.97 |
| Curaleaf Holdings (CURLF) | Canada | $1.472B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.459B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.394B | 61.09 |
| AdaptHealth (AHCO) | United States | $1.368B | 19.80 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.159B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.075B | 319.00 |
| Capricor Therapeutics (CAPR) | United States | $1.056B | 0.00 |
| InMode (INMD) | Israel | $1.051B | 11.87 |
| Tilray Brands (TLRY) | Canada | $0.867B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.862B | 0.00 |
| Omeros (OMER) | United States | $0.831B | 0.00 |
| Valneva SE (VALN) | France | $0.788B | 0.00 |
| CeriBell (CBLL) | United States | $0.750B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.594B | 16.09 |
| Brainsway (BWAY) | Israel | $0.455B | 77.50 |
| Verano Holdings (VRNO) | United States | $0.450B | 0.00 |
| Cerus (CERS) | United States | $0.446B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.402B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.372B | 0.00 |
| Evolus (EOLS) | United States | $0.318B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.304B | 24.24 |
| Quanterix (QTRX) | United States | $0.304B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.255B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.228B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.222B | 130.67 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| OraSure Technologies (OSUR) | United States | $0.209B | 0.00 |
| Organigram Global (OGI) | Canada | $0.204B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.199B | 0.00 |
| High Tide (HITI) | Canada | $0.198B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.198B | 17.75 |
| Sanara MedTech (SMTI) | United States | $0.196B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.188B | 0.00 |
| Accendra Health (ACH) | United States | $0.176B | 1.76 |
| Apyx Medical (APYX) | United States | $0.168B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.154B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.135B | 0.00 |
| Fonar (FONR) | United States | $0.116B | 16.77 |
| MacroGenics (MGNX) | United States | $0.111B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.109B | 0.00 |
| Biote (BTMD) | United States | $0.104B | 4.54 |
| Exagen (XGN) | United States | $0.087B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 23.50 |
| Sharps Technology (STSS) | United States | $0.049B | 0.00 |
| Nephros (NEPH) | United States | $0.049B | 35.15 |
| Rockwell Medical (RMTI) | United States | $0.045B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.043B | 0.00 |
| Veru (VERU) | United States | $0.041B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.035B | 17.86 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.021B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Flora Growth (ZSTK) | United States | $0.008B | 0.00 |
| INLIF (INLF) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |